

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/380734192>

Unveiling the Link: Anemia as a Risk Factor for Cerebrovascular Accidents

Article in *Haematology International Journal* · May 2024

DOI: 10.23880/hij-16000252

CITATIONS

0

READS

3

1 author:



[Emmanuel Ifeanyi Obeagu](#)

Kampala International University (KIU)

1,686 PUBLICATIONS 23,400 CITATIONS

[SEE PROFILE](#)



Unveiling the Link: Anemia as a Risk Factor for Cerebrovascular Accidents

Emmanuel Ifeanyi Obeagu*

Department of Medical Laboratory Science, Kampala International University, Uganda

***Corresponding author:** Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, Tel: +2348037369912; Email: emmanuelobeagu@yahoo.com

Review Article

Volume 8 Issue 1

Received Date: May 09, 2024

Published Date: May 21, 2024

DOI: 10.23880/hij-16000252

Abstract

Anemia, a prevalent hematological condition characterized by decreased red blood cell count or hemoglobin levels, has emerged as a significant risk factor for cerebrovascular accidents (CVAs) and commonly known as strokes. This review explores the intricate connection between anemia and the occurrence of CVAs, elucidating the underlying mechanisms and clinical implications. Anemia contributes to stroke risk through multiple pathways, including impaired oxygen delivery to the brain, alterations in cerebral hemodynamics, and disruption of neurovascular homeostasis. Furthermore, iron deficiency anemia's predominant etiology-not only exacerbates hypoxia but also compromises neuronal integrity, predisposing individuals to ischemic and hemorrhagic stroke events. The hemodynamic consequences of anemia, including cerebral hypo-perfusion and increased thromboembolic risk, underscore its role as a silent culprit in stroke pathogenesis. Anemia-induced alterations in blood viscosity, endothelial dysfunction, and compensatory vasodilation contribute to the vulnerability of cerebral vasculature to ischemic insults. Moreover, iron deficiency exacerbates neurocognitive impairment and promotes neuro degeneration, exacerbating the risk of vascular cognitive decline and hemorrhagic stroke. Routine screening for anemia, particularly in high-risk populations, coupled with targeted interventions aimed at correcting underlying etiologies and optimizing hemoglobin levels, is essential for mitigating stroke risk and improving clinical outcomes.

Keywords: Anemia; Cerebrovascular Accidents; Stroke; Risk Factors; Hemoglobin; Iron Deficiency

Abbreviations: ESAs: Erythropoiesis-Stimulating Agents; IDA: Iron Deficiency Anemia; MCV: Mean Corpuscular Volume; CVAs: Cerebrovascular Accidents.

Introduction

Cerebrovascular accidents (CVAs), commonly referred to as strokes, constitute a significant global health burden, accounting for substantial morbidity and mortality worldwide [1]. While traditional risk factors such as hypertension, diabetes mellitus, and dyslipidemia have long been recognized

as primary contributors to stroke occurrence, emerging evidence has unveiled an often-overlooked player in stroke pathogenesis: anemia. Anemia, characterized by a deficiency in red blood cell count or hemoglobin concentration, has garnered increasing attention for its potential role as a predisposing factor for cerebrovascular events [2-4]. Anemia represents a multifaceted hematological disorder with diverse etiologies, including nutritional deficiencies, chronic diseases, and inherited or acquired hematological conditions. Despite its prevalence and clinical significance, anemia often remains underdiagnosed or undertreated,

particularly in vulnerable populations such as the elderly, individuals with chronic medical conditions, and women of reproductive age. The consequences of anemia extend far beyond its hematological manifestations, encompassing systemic effects on various organ systems, including the cardiovascular and central nervous systems. As such, understanding the impact of anemia on cerebrovascular health is paramount for comprehensive stroke prevention and management strategies [5-8].

Central to the pathophysiology of anemia-related cerebrovascular events is the disruption of oxygen delivery to the brain, a critical determinant of cerebral tissue viability and function [9]. Decreased hemoglobin levels compromise the blood's oxygen-carrying capacity, leading to tissue hypoxia and metabolic derangements within the cerebral microenvironment. The brain, with its high metabolic demands and susceptibility to ischemic insults, is particularly vulnerable to the consequences of impaired oxygenation. Furthermore, anemia-induced alterations in cerebral hemodynamics, including compensatory vasodilation and dysregulated blood flow auto-regulation, contribute to the pathogenesis of ischemic stroke by exacerbating cerebral hypoperfusion and promoting thromboembolic events. Iron deficiency, the most common cause of anemia worldwide, assumes a pivotal role in the context of cerebrovascular health. Beyond its canonical function in erythropoiesis, iron plays a crucial role in various neurophysiological processes, including neurotransmitter synthesis, myelination, and oxidative metabolism. Consequently, iron deficiency anemia (IDA) not only compromises oxygen delivery to the brain but also disrupts neuronal integrity and function, predisposing individuals to cognitive impairment and neurodegenerative diseases. Moreover, iron deficiency exacerbates the risk of hemorrhagic stroke by promoting vascular fragility and impairing coagulation pathways, further underscoring the significance of addressing iron status in stroke prevention and management [10-13]. The complex relationship between anemia and stroke extends beyond mere hematological abnormalities, encompassing systemic inflammatory responses, endothelial dysfunction, and neurovascular remodeling. Chronic inflammation, a common feature of many anemia etiologies, contributes to endothelial dysfunction and a prothrombotic milieu, thereby augmenting the risk of cerebrovascular events. Additionally, anemia-induced alterations in neurovascular coupling and cerebral autoregulation predispose individuals to hemodynamic instability and exacerbate the consequences of cerebral ischemia [13-16].

Anemia: A Silent Culprit

Anemia, often referred to as a silent culprit, is a prevalent hematological condition characterized by a deficiency in the

number of red blood cells or the concentration of hemoglobin in the blood. Despite its pervasive nature, anemia frequently goes unnoticed or is dismissed as a benign condition, overshadowed by more overt health concerns. However, beneath its seemingly innocuous facade lies a significant risk factor for a myriad of adverse health outcomes, including cerebrovascular accidents (CVAs), commonly known as strokes. The insidious nature of anemia lies in its ability to quietly undermine the body's physiological equilibrium, compromising vital organ function and predisposing individuals to potentially life-threatening events [17-19]. Central to the pathophysiology of anemia is its impact on oxygen delivery to tissues, a fundamental process essential for cellular metabolism and energy production. Hemoglobin, the oxygen-carrying protein within red blood cells, plays a pivotal role in facilitating oxygen transport from the lungs to peripheral tissues. In the context of anemia, diminished hemoglobin levels impair the blood's capacity to deliver oxygen effectively, leading to tissue hypoxia and metabolic dysfunction. The brain, with its high metabolic demands and exquisite sensitivity to oxygen deprivation, is particularly susceptible to the deleterious effects of anemia-induced hypoxia. Prolonged hypoxic exposure predisposes cerebral tissue to ischemic injury, laying the groundwork for the development of ischemic strokes, the most common subtype of CVA [20-23]. Beyond its direct effects on oxygen transport, anemia exerts systemic repercussions that further potentiate its role as a silent culprit in stroke pathogenesis. Chronic anemia triggers compensatory mechanisms aimed at maintaining tissue perfusion, including cerebral vasodilation and increased cardiac output. While these adaptive responses serve to mitigate the immediate consequences of tissue hypoxia, they may inadvertently exacerbate cerebrovascular instability and predispose individuals to hemodynamic fluctuations. Moreover, anemia-induced alterations in blood viscosity and coagulation profiles contribute to a prothrombotic state, augmenting the risk of thromboembolic events, including ischemic strokes. Thus, the insidious nature of anemia lies not only in its direct impact on oxygen delivery but also in its systemic effects on vascular homeostasis, collectively increasing the propensity for cerebrovascular accidents [24-27].

The Hemodynamic Cascade

Anemia, characterized by a deficiency in red blood cells or hemoglobin, sets in motion a complex cascade of hemodynamic alterations that significantly impact cerebrovascular health. At the heart of this cascade lies the disruption of cerebral perfusion dynamics, precipitating a series of events that culminate in cerebrovascular accidents (CVAs), commonly known as strokes. Understanding the intricacies of this hemodynamic cascade is essential for unraveling the hidden connection between anemia and

stroke, shedding light on both the pathophysiological mechanisms and clinical implications of this relationship [28-30]. Diminished hemoglobin levels associated with anemia compromise the blood's oxygen-carrying capacity, leading to tissue hypoxia and metabolic derangements within the cerebral microenvironment [31]. In response to hypoxic stimuli, cerebral blood vessels undergo vasodilation as a compensatory mechanism to augment oxygen delivery to the brain. While this vasodilatory response initially serves to alleviate tissue hypoxia, it may ultimately exacerbate cerebrovascular instability and predispose individuals to hemodynamic fluctuations. Furthermore, chronic anemia elicits adaptive changes in cardiac function, including increased heart rate and stroke volume, in an effort to maintain systemic perfusion pressure. However, these hemodynamic adaptations may inadvertently exacerbate cerebrovascular dysfunction, particularly in the context of impaired autoregulation and vascular reactivity. The hemodynamic consequences of anemia extend beyond mere alterations in cerebral blood flow, encompassing systemic effects on vascular integrity and coagulation homeostasis. Reduced blood viscosity secondary to anemia promotes turbulent flow patterns and endothelial dysfunction, predisposing individuals to a prothrombotic state [32]. Endothelial activation and platelet aggregation further potentiate the risk of thromboembolic events, including ischemic strokes. Moreover, anemia-induced changes in coagulation profiles, including alterations in fibrinogen levels and platelet function, contribute to the formation of intravascular thrombi, occluding cerebral arteries and precipitating ischemic infarctions. Thus, the hemodynamic cascade initiated by anemia encompasses not only cerebral perfusion dynamics but also systemic alterations in vascular function and thrombotic propensity, collectively increasing the susceptibility to cerebrovascular accidents.

Iron Deficiency: Bridging the Gap

Iron deficiency, a leading cause of anemia worldwide, emerges as a pivotal player in the intricate relationship between anemia and cerebrovascular accidents (CVAs) [33]. Beyond its conventional role in erythropoiesis, iron assumes multifaceted functions within the central nervous system, bridging the physiological gap between hematological abnormalities and neurological manifestations. At the forefront of iron deficiency's impact on cerebrovascular health lies its pivotal role in oxygen transport and utilization within the brain. Iron serves as an essential cofactor in numerous enzymatic reactions involved in oxidative metabolism and neurotransmitter synthesis, facilitating neuronal function and synaptic transmission [34]. Consequently, iron deficiency compromises neuronal integrity and function, predisposing individuals to cognitive impairment and neurodegenerative diseases. Moreover, iron deficiency exerts systemic effects

on vascular function, disrupting endothelial integrity and promoting a prothrombotic milieu, thereby augmenting the risk of thromboembolic events, including ischemic strokes. Thus, iron deficiency acts as a critical mediator linking anemia to cerebrovascular dysfunction, exacerbating the predisposition to stroke through both hematological and neurological mechanisms. The impact of iron deficiency on cerebrovascular health extends beyond its direct effects on neuronal function and vascular homeostasis, encompassing broader systemic implications for neurological development and neurodegenerative processes [35]. Iron deficiency in early life disrupts critical periods of brain development, impairing myelination and synaptic pruning processes that are essential for cognitive function and behavioral outcomes. Moreover, iron deficiency in adulthood exacerbates the risk of neurodegenerative diseases such as Alzheimer's and Parkinson's, highlighting the enduring consequences of iron dysmetabolism on long-term neurological health. Thus, addressing iron deficiency represents a crucial therapeutic strategy not only for mitigating the risk of stroke but also for promoting optimal brain development and preserving cognitive function across the lifespan.

Clinical Implications and Management Strategies

Recognizing anemia as a significant modifiable risk factor for cerebrovascular accidents (CVAs) holds profound clinical implications for stroke prevention and management. Given the intricate interplay between anemia and stroke, implementing targeted interventions aimed at correcting underlying hematological abnormalities and optimizing cerebrovascular health is essential for improving clinical outcomes and reducing the burden of stroke-related morbidity and mortality. Routine screening for anemia, particularly in high-risk populations such as the elderly, individuals with chronic medical conditions, and pregnant women, is paramount for early detection and intervention [36]. Comprehensive assessment of hematological parameters, including hemoglobin levels, mean corpuscular volume (MCV), and serum ferritin concentrations, enables clinicians to identify individuals at increased risk of anemia-related cerebrovascular events. Moreover, integrating clinical risk stratification tools, such as the CHA2DS2-VASc score, which incorporates anemia as a risk factor for thromboembolic events, facilitates personalized risk assessment and targeted management strategies in individuals with concomitant cardiovascular risk factors.

Management strategies for anemia-related stroke prevention encompass a multifaceted approach aimed at correcting underlying etiologies, replenishing iron stores, and optimizing hemoglobin levels. Addressing nutritional deficiencies, particularly iron, vitamin B12, and folate,

through dietary modifications and supplementation plays a central role in restoring erythropoietic function and mitigating stroke risk. Moreover, targeted interventions aimed at managing comorbidities contributing to anemia, such as chronic kidney disease, inflammatory disorders, and gastrointestinal bleeding, are essential for addressing the underlying pathophysiological mechanisms and preventing recurrent cerebrovascular events. Iron supplementation represents a cornerstone of therapeutic intervention in individuals with iron deficiency anemia (IDA), aiming to replenish iron stores and optimize hemoglobin levels [37]. Oral iron supplementation is often recommended as first-line therapy for mild to moderate IDA, with intravenous iron therapy reserved for individuals with severe anemia or intolerance to oral iron preparations. Additionally, erythropoiesis-stimulating agents (ESAs) may be considered in select cases, particularly in individuals with concomitant chronic kidney disease or refractory anemia. However, cautious use of ESAs is warranted, given the potential risks of thromboembolic events and cardiovascular complications associated with their use. Beyond hematological interventions, multidisciplinary management approaches encompassing lifestyle modifications, cardiovascular risk factor optimization, and coordinated care among healthcare providers are instrumental in addressing the complex interplay between anemia and cerebrovascular disease [38]. Encouraging regular physical activity, smoking cessation, and adherence to a heart-healthy diet rich in fruits, vegetables, and whole grains promotes cardiovascular health and reduces the risk of stroke. Moreover, close monitoring of blood pressure, glycemic control, and lipid levels helps mitigate additional vascular risk factors, further lowering the risk of cerebrovascular events in individuals with anemia.

Conclusion

The intricate relationship between anemia and cerebrovascular accidents (CVAs) underscores the significance of recognizing anemia as a modifiable risk factor in stroke prevention and management. Anemia, characterized by a deficiency in red blood cells or hemoglobin, exerts multifaceted effects on cerebrovascular health, disrupting cerebral perfusion dynamics, promoting vascular instability, and potentiating thromboembolic events. Central to the pathophysiology of anemia-related strokes is the disruption of oxygen delivery to the brain, precipitating tissue hypoxia and metabolic dysfunction within the cerebral microenvironment. Furthermore, iron deficiency-anemia's predominant etiology exacerbates the risk of stroke by compromising neuronal function, disrupting vascular homeostasis, and promoting a prothrombotic milieu. Routine screening for anemia, coupled with comprehensive assessment of cardiovascular risk factors, facilitates personalized risk stratification and tailored management strategies in at-risk populations.

References

1. Losseff N, Adams M, Brown MM, Grieve J, Simister R (2016) Stroke and Cerebrovascular Diseases. *Neurology: A Queen Square Textbook* pp: 133-185.
2. Hare GMT, Tsui AKY, McLaren AT, Ragoonanan TE, Yu J, et al. (2008) Anemia and cerebral outcomes: many questions, fewer answers. *Anesth Analg* 107(4): 1356-1370.
3. Obeagu EI (2021) Comparative Study of Serum Iron and Hemoglobin Levels of Cord Blood of Normal Neonates and that of Maternal Blood in Federal Medical Centre Owerri. *Journal of Clinical and Laboratory Research* 4(1): 1-3.
4. Obeagu EI, Aneke J, Okafor CN, Esseim UC, Ochei KC, et al. (2016) Assessment of Serum Iron Status of Malnourished Infants in Umuahia, Abia State, Nigeria. *Sch J App Med Sci* 4: 4384-4387.
5. Esposito G, Dottori L, Pivetta G, Ligato I, Dilaghi E, et al. (2022) Pernicious anemia: the hematological presentation of a multifaceted disorder caused by cobalamin deficiency. *Nutrients* 14(8):1672.
6. Obeagu EI, Eze VU, Alaebob EA, Ochei KC (2016) Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BiolInnovation* 5(4): 464-471.
7. Obeagu EI, Opoku D, Obeagu GU (2023) Burden of nutritional anaemia in Africa: A Review. *Int J Adv Res Biol Sci* 10(2): 160-163.
8. Obeagu EI, Okeke EI, Anonde AC (2016) Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int J Curr Res Biol Med* 1(2): 1-5.
9. Xu JZ, Thein SL (2022) Revisiting anemia in sickle cell disease and finding the balance with therapeutic approaches. *Blood* 139(20): 3030-3039.
10. Obeagu EI, Mohamod AH (2023) An update on Iron deficiency anaemia among children with congenital heart disease. *Int J Curr Res Chem Pharm Sci* 10(4): 45-48.
11. Obeagu EI, Oshim IO, Ochei KC, Obeagu GU (2016) Iron and blood donation: A Review. *Int J Curr Res Med Sci* 2(10): 16-48.
12. Obeagu EI, Obeagu GU, Emeonye OP, Jakheng SP (2022) An Upadte on Interleukin 6 And Iron Status of Volleyball Players. *Madonna University journal of Medicine and*

- Health Sciences 2(2): 41-74.
13. Fekete R, Simats A, Biro E, Cserep C, Schwarcz AD, et al. (2023) Infection-induced vascular inflammation in COVID-19 links focal microglial dysfunction with neuropathologies through IL-1/IL-6-related systemic inflammatory states. *bioRxiv* 2023: 1-66.
 14. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, et al. (2017) Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. *Ann Clin Lab Res* 5(4): 206.
 15. Obeagu EI, Anierobi CC, Eze GC, Chukwueze CM, Makonyonga RD (2022) Evaluation of Plasma Levels of Interleukin 6 and Iron Status of Volleyball Players in a Nigerian University. *Journal of Advances in Medical and Pharmaceutical Sciences* 24(6): 18-23.
 16. Obeagu EI, Obeagu GU, Guevara ME, Okafor CJ, Bot YS, et al. (2022) Evaluation of Plasma Levels of Interleukin 6 and Iron of Volleyball Players Based on Heights and Weight of a Nigerian University Students. *Asian Journal of Medicine and Health* 20(10): 147-152.
 17. Obeagu E, Felix CE, MTB O, Chikodili UM, Nchekwubedi CS, et al. (2021) Studies on some cytokines, CD4, iron status, hepcidin and some haematological parameters in pulmonary tuberculosis patients based on duration of treatment in Southeast, Nigeria. *African Journal of Biological Sciences* 3(1): 146-156.
 18. Okoroiwu IL, Madu JUC, Obeagu EI, Vincent CC, Ochiabuto OM, et al. (2021) Evaluation of Iron Status, Haemoglobin and Protein Levels of Pregnant Women in Owerri Metropolis. *Journal of Pharmaceutical Research International* 33(27A): 36-43.
 19. Obeagu EI (2020) Erythropoietin in Sickle Cell Anaemia: A Review. *International Journal of Research Studies in Medical and Health Sciences* 5(2): 22-28.
 20. Kuhn V, Diederich L, Keller TS, Kramer CM, Luckstadt W, et al. (2017) Red blood cell function and dysfunction: redox regulation, nitric oxide metabolism, anemia. *Antioxid Redox Signal* 26(13): 718-742.
 21. Obeagu EI, Ezimah AC, Obeagu GU (2016) Erythropoietin in the anaemias of pregnancy a review. *Int J Curr Res Chem Pharm Sci* 3(3): 10-18.
 22. Obeagu EI, Agreen FC (2023) Anaemia among pregnant women A review of African pregnant teenagers. *J Pub Health Nutri* 6(1): 138.
 23. Obeagu EI, Nwazu ME, Obeagu GU (2022) Evaluation of plasma levels of interleukin 6 and iron status based on sleeping patterns of students in a Nigerian University. *Int J Curr Res Med Sci* 8(9): 1-6.
 24. Cui P, Cullough LD, Hao J (2021) Brain to periphery in acute ischemic stroke: mechanisms and clinical significance. *Front Neuroendocrinol* 63: 100932.
 25. Edward U, Osuorji VC, Nnodim J, Obeagu EI (2022) Evaluation of Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital Owerri. *Madonna University Journal of Medicine and Health Sciences* 2(1): 218-234.
 26. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU (2023) Hyperthyroidism in sickle cell anaemia. *Int J Adv Res Biol Sci* 10(3): 81-89.
 27. Obeagu EI, Babar Q (2021) Recent advances in understanding of Haemochromatosis: A burning issue of life. *Int J Curr Res Med Sci* 7(7): 23-28.
 28. Linklater A, Higgs V (2016) Red blood cells and hemoglobin Monitoring and Intervention for the Critically Ill Small Animal: The Rule of 20 pp: 157-176.
 29. Obeagu EI, Okoroiwu IL, Azuonwu O (2018) An update on hypoxic regulation of iron homeostasis and bone marrow environment. *Int J Curr Res Med Sci* 4(10): 42-48.
 30. Edward H, Obeagu EI (2024) Assessment of the Serum Iron Status of Preeclampsia Subjects in Aba, Abia State. *Elite Journal of Haematology* 2(1): 10-18.
 31. Krishna SG, Syed A, Bryant J, Tobias JD (2014) The physiology of anemia and the threshold for blood transfusion. *Transfusion Free Medicine and Surgery* 61-82.
 32. Mozos I (2015) Mechanisms linking red blood cell disorders and cardiovascular diseases. *Biomed Res Int*.
 33. Kumar A (2018) A Study to Correlate Red Cell Distribution Width and Clinical Stroke Scoring Systems in Acute Ischemic Stroke.
 34. Udipi S, Ghugre P, Gokhale C (2012) Iron oxidative stress and health. *Oxidative Stress Molecular Mechanisms and Biological Effects in Tech* 73-108.
 35. Zimmerman B, Rypma B, Gratton G, Fabiani M (2021) Age-related changes in cerebrovascular health and their effects on neural function and cognition A comprehensive review. *Psychophysiology* 58(7): e13796.
 36. Mwangi MN, Mzembe G, Moya E, Verhoef H (2021) Iron deficiency anaemia in sub Saharan Africa a review of

current evidence and primary care recommendations for high-risk groups. *The Lancet Haematology* 8(10): e732-43.

37. Schaefer B, Meindl E, Wagner S, Tilg H, Zoller H (2020) Intravenous iron supplementation therapy. *Mol Aspects*

Med 75: 100862.

38. Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, et al. (2016) The European hematology association roadmap for European hematology research a consensus document. *Haematologica* 101(2): 115-208.